1. Home
  2. ALG vs GERN Comparison

ALG vs GERN Comparison

Compare ALG & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALG
  • GERN
  • Stock Information
  • Founded
  • ALG 1955
  • GERN 1990
  • Country
  • ALG United States
  • GERN United States
  • Employees
  • ALG N/A
  • GERN N/A
  • Industry
  • ALG Industrial Machinery/Components
  • GERN Biotechnology: Pharmaceutical Preparations
  • Sector
  • ALG Industrials
  • GERN Health Care
  • Exchange
  • ALG Nasdaq
  • GERN Nasdaq
  • Market Cap
  • ALG 2.3B
  • GERN 2.5B
  • IPO Year
  • ALG 1993
  • GERN 1996
  • Fundamental
  • Price
  • ALG $188.49
  • GERN $3.49
  • Analyst Decision
  • ALG Strong Buy
  • GERN Strong Buy
  • Analyst Count
  • ALG 3
  • GERN 10
  • Target Price
  • ALG $231.33
  • GERN $7.05
  • AVG Volume (30 Days)
  • ALG 93.1K
  • GERN 7.6M
  • Earning Date
  • ALG 02-20-2025
  • GERN 11-07-2024
  • Dividend Yield
  • ALG 0.55%
  • GERN N/A
  • EPS Growth
  • ALG N/A
  • GERN N/A
  • EPS
  • ALG 9.93
  • GERN N/A
  • Revenue
  • ALG $1,660,732,000.00
  • GERN $29,480,000.00
  • Revenue This Year
  • ALG N/A
  • GERN $32,021.10
  • Revenue Next Year
  • ALG $0.72
  • GERN $298.14
  • P/E Ratio
  • ALG $18.97
  • GERN N/A
  • Revenue Growth
  • ALG 0.12
  • GERN 9199.68
  • 52 Week Low
  • ALG $163.74
  • GERN $1.64
  • 52 Week High
  • ALG $231.40
  • GERN $5.34
  • Technical
  • Relative Strength Index (RSI)
  • ALG 40.70
  • GERN 29.57
  • Support Level
  • ALG $191.60
  • GERN $3.75
  • Resistance Level
  • ALG $201.03
  • GERN $4.00
  • Average True Range (ATR)
  • ALG 4.77
  • GERN 0.17
  • MACD
  • ALG -1.21
  • GERN -0.04
  • Stochastic Oscillator
  • ALG 0.98
  • GERN 5.51

About ALG Alamo Group Inc.

Alamo Group Inc is engaged in the design and manufacturing of agricultural equipment and infrastructure maintenance equipment. Its products include tractor-mounted mowing and other vegetation maintenance equipment, street sweepers, excavators, vacuum trucks, snow removal equipment, leaf collection equipment, pothole patchers, zero-turn radius mowers, agricultural implements, and related aftermarket parts. The company's reportable segments are Vegetation Management and Industrial Equipment. It generates a majority of its revenue from Vegetation Management. Geographically, the company generates majority of the revenue from the United States.

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Share on Social Networks: